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In 1581 Rembert Dodoens wrote “Medicinalium observationum exempla rara, recognita et aucta” a Latin book
about the diagnosis and treatment of disorders with a low prevalence.The “orphan drug-movement” is believed to have been
initiated only recently with the Orphan Drug Act of
1983 in the United States of America, which was
intended to stimulate research and commercialization of
medicinal products (“orphan drugs”) intended for the
in-vivo diagnosis, prevention and treatment of dis-
eases with a low prevalence (“rare diseases”). But was
there any interest in disorders with a low prevalence
before last century?
Rembert Dodoens was a Flemish physician also known
as Rembertus Dodonaeus, who was born in Mechelen
(now Belgium) on the 29th of June 1517. He did his
studies at the Collegium Trilingue (founded by Desiderius
Erasmus in 1518) in Leuven as did Andreas Vesalius
and at the University of Leuven where he graduated as
a physician in 1535. After his studies he established
himself as a physician in his hometown Mechelen and
turned down positions as professor in medicine at the
University of Leuven and as court physician of King
Philip II of Spain. After extensive travelling, he joined
the Faculty of Medicine at Leiden University as a pro-
fessor in 1582 where he died on the 10th of March
1585. His most famous book is his Cruydenboeck
(“herb book”), which is the the first pharmacopoeia of
medicinal herbs. In 1581, he wrote Medicinalium
observationum exempla rara. Two copies of this book
written in Latin are in the Tabularium of the central li-
brary of the University in Leuven: the first edition
(1581, 397 pages) is catalogued as DPA510 and the
second (1585, printed by the famous Christopher Plantijn
in Antwerp) is catalogued as 7A875. In 1543, Andreas
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Humani Corporis Fabrica, based on dissections of human
bodies. In 1546, Hieronymus Fracastorius, a colleague of
Vesalius in Padua, suggested in his De Contagione et
contagiosis Morbis that epidemic diseases could be caused
by the transfer of tiny particles.
Medicinalium observationum exempla rara, recognita
et aucta. Accessere et alia quaedam, quorum elenchum
pagina post praefationem exhibit by Rembert Dodoens
medici Caesarei along with Valesco de Tarenta,
Alexander Benedictus, Antonio Benivieni, Maternus
Cholinus, Mathias Cornax, Achilles Pirmin Gasser and
Gilles de Hertoghe. After a general introduction and a list
of cited authors (including Vesalius and Fracastorius),
Rembert Dodoens gives extensive list of some 200 rare
diseases in the 16th century such as Aneurisma, Calculus
in vesica (stone in the bladder), Catalepsis (seizure),
Diabetes, Dysenteria, Gemini pueri (twins), Lapides in
vessica fellis (gall stones), Mania cum Melancholia
affinitatem habet (mania with melancholia) Scorbutus,
Tetanos, Vermis in vesica (worms in the bladder) and
Vomitus sanguinis (vomiting blood). These are all
macroscopic (“de visu et de manu”) or organoleptic
observations as Antoni Van Leeuwenhoek (1632–1723)
started to use a microscope in cell- and microbiology only
in 1674. Also Syndromes Without a Name (SWAN) are
mentioned such as Memoria amisa ac recuperate (“he lost
his memory and recovered it”), Respirandi difficultas
(difficulty breathing) and De pedis tumore quem Arabes
Elephantiam appellant” (swelling of the feet called ele-
phantiasis by the Arabs).
For surgical procedures Dodoens called upon his
local barber-surgeons (amputatio) or stone-cutters
(lithotomia). For pharmacological treatment Dodoens
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Kracht ende Werckinghe” (growing place and time,
name, identification, pharmacological activity) of 942
plants. Operating procedures for the production of his
“orphan drugs” from plant material (bolus, confectio,
decoctum, electuarium, hostia, pilula, potio, pulvis, syru-
pus, trochiscus for internal use and balneum, cauterium,
clysterium, collyrium, emplastrum, gargarisma, lotio,
unguentum for external use) are given at the end of some
monographs.
The standardization of these compounding procedures
by local pharmacists continued further with the publica-
tion of several city and (supra)national pharmacopoeias.
Only at the end of the 19th century the pharmaceutical
industry will take over the manufacturing of medica-
tions. In 2012, the European Medical Agency accorded a
Market Authorization to the orphan drug Nexobrid, a
purified extract from pineapple (Ananas comosus). Col-
chicine, the active ingredient of Colchicum autumnale
(Cruydenboeck Part 3, Plant 40), is still used today off-
label for the treatment of ultra-rare auto-inflammatory
diseases. Off-label use was not mentioned as the FDA
required the first package insert only in 1968. Home
therapy was done by pharmacists administering clysters
at home.
Throughout the Middle Ages, to be diagnosed with a
(rare) disease had major social (“stigmatization”) and
medicinal implications for the individual. Some commu-
nities, knowing the importance of an accurate diagnosis,
established multidisciplinary groups (“expert centers”) to
review suspected cases. Representatives of the church,
physicians and people with the disease (“patients’ repre-
sentatives”) were typically members of these groups.
Cousin marriage was common at that time in Europe,
which most probably resulted in multiple genetic dis-
eases. These disorders could not yet be diagnosed on
DNA as James Watson and Francis Crick discovered the
double helix only in 1953. The first description of a rare
disease attributed to inheritance (alkaptonuria) was by
Archibald Garrod in 1902 on the basis of proteins not
DNA. Children were born at home from teenage house-
wives sometimes with the help of a midwife following
the guidelines of Eucharius Rhodion’s Der Rosengarten
(1513). Long-time breastfeeding by the mother or by a
wet nurse was general practice. Infanticide became ex-
ceptional in the 16th century, and unwanted children
were left at the door of church or abbey, and the clergy
was assumed to take care of their upbringing.
William Harvey (1578–1657) was the first to describe
correctly the systemic circulation of blood pumped to
the brain and body by the heart. He is also famous for
his quote on rare diseases: Nature is nowhere accus-
tomed more openly to display her secret mysteries than
in cases where she shows traces of her workings apartfrom the beaten path; nor is there any better way to ad-
vance the proper practice of medicine than to give our
minds to the discovery of the usual law of nature by the
careful investigation of cases of rarer forms of disease.
For it has been found in almost all things, that what they
contain of useful or of applicable nature, is hardly per-
ceived unless we are deprived of them, or they become
deranged in some way.
Over the last 500 years at least, there has always been
interest on the part of the medical and pharmaceutical
profession in the diagnosis and treatment of disorders
with a low prevalence. But of course, diagnostic
(uroscopy as the lab test) and surgical procedures
have changed tremendously over time. Life-style changes
(scorbutus/vitamin C; dysenteria/better quality of drinking
water) and vaccinations (tetanos/Clostridium) have almost
eliminated some and a better understanding of the
diseases has led to prevention and better (intravenous)
therapy. Compounding medications following Standard
Operating Procedures and Good Manufacturing Practice
is still practiced today but most of the medicinal products
for the prevention, diagnosis and treatment of a limited
number of rare diseases are now commercially available.
More basic research and randomized clinical trials are
needed for the cure of patients with other rare –- and
ultra-rare—diseases.
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